Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
127.3 USD | +0.31% | +1.94% | +16.94% |
Financials (USD)
Sales 2024 * | 63.82B | Sales 2025 * | 68.17B | Capitalization | 322B |
---|---|---|---|---|---|
Net income 2024 * | 19.48B | Net income 2025 * | 21.78B | EV / Sales 2024 * | 5.35 x |
Net Debt 2024 * | 19.65B | Net Debt 2025 * | 7.53B | EV / Sales 2025 * | 4.83 x |
P/E ratio 2024 * |
16.4
x | P/E ratio 2025 * |
14.3
x | Employees | 71,000 |
Yield 2024 * |
2.42% | Yield 2025 * |
2.55% | Free-Float | 70.75% |
Latest transcript on Merck & Co., Inc.
1 day | +0.92% | ||
1 week | +0.59% | ||
Current month | -3.80% | ||
1 month | +2.49% | ||
3 months | +6.29% | ||
6 months | +23.64% | ||
Current year | +16.44% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 215 M€ | +12.92% | - | |
5.61% | 18 M€ | +2.56% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 127.5 | +0.44% | 1 888 363 |
24-04-22 | 126.9 | +0.92% | 7,805,992 |
24-04-19 | 125.8 | +0.44% | 8,404,345 |
24-04-18 | 125.2 | -0.11% | 5,992,700 |
24-04-17 | 125.4 | +0.25% | 6,122,908 |
Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.44% | 322B | |
+25.46% | 659B | |
+25.38% | 557B | |
-4.86% | 359B | |
+8.34% | 297B | |
+6.13% | 215B | |
+2.93% | 210B | |
-7.65% | 200B | |
-8.79% | 149B | |
-5.59% | 146B |
- Stock Market
- Equities
- MRK Stock